Associations between DNA repair SNPs and outcomes to platinum-based chemotherapy in ovarian cancer patients
Ruszczyk, Melanie Ursula
MetadataShow full item record
Objectives . Response to chemotherapy is affected by an individual's particular genetic makeup. Polymorphisms in DNA repair genes may play a role in the outcome to chemotherapy. The following study was for the purpose of exploring associations between certain DNA repair SNPs and the outcomes to platinum-based chemotherapy in ovarian cancer patients. Methods . Associations between DNA repair SNPs and outcomes to chemotherapy were examined within the HOPE project, a population-based case-control study of women with ovarian cancer. Once consented, women were interviewed asked for a blood sample as well as their permission to access their medical records since the time of diagnosis. Genotyping for DNA repair SNPs, XPD 751, XRCC1 399, and MGMT 143 was performed with MALDI-ToF. Outcomes and genotypes were analyzed using unconditional logistic regression. Kaplan-Meier curves and proportional Cox regression models were utilized for survival analysis. Results . We did not observe significant associations between any SNPs under investigation and clinical outcomes, with the exception of the XRCC1 399 genotype containing one or two variant alleles, which was associated inversely with the outcome no response to chemotherapy (adjusted OR 0.22 95%CI [0.07,0.69].) Conclusions . DNA repair SNPs may have some influence the outcome to platinum-based chemotherapy in this population of ovarian cancer patients. One or two variant allele genotypes of XRCC1 399 was associated with a higher initial response to platinum-based chemotherapy. These results add to the base of information regarding individualized treatment for women with ovarian cancer with the hope of improving outcomes.